MA52414A - Anticorps agonistes de pd-1 et leurs utilisations - Google Patents

Anticorps agonistes de pd-1 et leurs utilisations

Info

Publication number: MA52414A
Authority: MA; Morocco
Prior art keywords: agonist antibodies; agonist; antibodies
Prior art date: 2018-03-02

Application number

MA052414A

Other languages

English (en)

Inventor

Qing Chai

Yiqing Feng

Kristin Paige Newburn

Stephanie Marie Truhlar

Petra Verdino

Pia Pauliina Yachi

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-03-02

Filing date

2019-02-22

Publication date

2021-01-06

2019-02-22 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2021-01-06 Publication of MA52414A publication Critical patent/MA52414A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA052414A 2018-03-02 2019-02-22 Anticorps agonistes de pd-1 et leurs utilisations MA52414A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201862637643P	2018-03-02	2018-03-02

Publications (1)

Publication Number	Publication Date
MA52414A true MA52414A (fr)	2021-01-06

Family

ID=65686121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA052414A MA52414A (fr)	2018-03-02	2019-02-22	Anticorps agonistes de pd-1 et leurs utilisations

Country Status (26)

Country	Link
US (1)	US10493148B2 (fr)
EP (1)	EP3759139A1 (fr)
JP (3)	JP7071521B2 (fr)
KR (2)	KR102536014B1 (fr)
CN (4)	CN111886253B (fr)
AR (1)	AR114127A1 (fr)
AU (2)	AU2019228474B2 (fr)
BR (1)	BR112020015983A2 (fr)
CA (1)	CA3092064C (fr)
CL (1)	CL2020002180A1 (fr)
CO (1)	CO2020010188A2 (fr)
CR (1)	CR20200375A (fr)
DO (1)	DOP2020000153A (fr)
EA (1)	EA202091809A1 (fr)
EC (1)	ECSP20053544A (fr)
IL (1)	IL276340A (fr)
JO (1)	JOP20200210A1 (fr)
MA (1)	MA52414A (fr)
MX (1)	MX2020009124A (fr)
PE (1)	PE20210045A1 (fr)
PH (1)	PH12020551463A1 (fr)
SA (1)	SA520420082B1 (fr)
SG (1)	SG11202008437WA (fr)
TW (1)	TWI708787B (fr)
WO (1)	WO2019168745A1 (fr)
ZA (1)	ZA202004601B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11207393B2 (en) *	2015-10-16	2021-12-28	President And Fellows Of Harvard College	Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
EP3596108A4 (fr)	2017-03-15	2020-12-23	Pandion Operations, Inc.	Immunotolérance ciblée
US10676516B2 (en)	2017-05-24	2020-06-09	Pandion Therapeutics, Inc.	Targeted immunotolerance
CR20190550A (es)	2017-06-05	2020-04-05	Janssen Biotech Inc	Anticuerpos que se unen específicamente a pd-1 y métodos de uso
US10174092B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
EP3768724A4 (fr) *	2018-03-20	2022-04-13	Wuxi Biologics Ireland Limited.	Nouveaux anticorps anti-pd-1
US11162079B2 (en)	2019-05-10	2021-11-02	The Regents Of The University Of California	Blood type O Rh-hypo-immunogenic pluripotent cells
US12221622B2 (en)	2019-05-10	2025-02-11	The Regents Of The University Of California	Modified pluripotent cells
BR112021023345A2 (pt)	2019-05-20	2022-02-01	Pandion Operations Inc	Imunotolerância com alvo em madcam
EP4107189A4 (fr) *	2020-02-21	2024-07-03	Pandion Operations, Inc.	Immunotolérance ciblée sur un tissu avec des agonistes de pd-1 ou des mutéines d'il-2
EP4107187A4 (fr)	2020-02-21	2024-07-03	Pandion Operations, Inc.	Immunotolérance ciblée sur un tissu avec un effecteur cd39
EP4139362A2 (fr) *	2020-04-22	2023-03-01	IGM Biosciences Inc.	Molécules de liaison multimères agonistes de pd-1
US20230183347A1 (en) *	2020-05-25	2023-06-15	Foundation For Biomedical Research And Innovation At Kobe	PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease
CR20220596A (es)	2020-05-26	2023-01-23	Boehringer Ingelheim Int	Anticuerpos anti-pd-1
WO2022239820A1 (fr)	2021-05-13	2022-11-17	公益財団法人神戸医療産業都市推進機構	Anticorps agoniste anti-pd-1 humain pour le traitement ou la prévention de maladies inflammatoires, et composition pharmaceutique le contenant
CN118284624A (zh)	2021-11-19	2024-07-02	米罗生物有限公司	Pd-1抗体及其用途
KR20240137086A (ko) *	2022-01-28	2024-09-19	조지아뮨 인코포레이티드	Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
CA3247422A1 (fr) *	2022-04-13	2023-10-19	The Regents Of The University Of California	Inhibition de cellules immunitaires par des engageurs de points de contrôle immunitaires
WO2024010861A2 (fr) *	2022-07-06	2024-01-11	Santa Ana Bio, Inc.	Méthodes et compositions pour le traitement de maladies auto-immunes, allergiques et inflammatoires
WO2024040206A2 (fr) *	2022-08-19	2024-02-22	Eli Lilly And Company	Anticorps agonistes de pd-1 et méthodes de traitement de maladies auto-immunes avec un anticorps agoniste de pd-1
EP4580674A2 (fr) *	2022-08-30	2025-07-09	Flagship Pioneering Innovations VI, LLC	Molécules de liaison à l'antigène ciblant la protéine 1 de mort cellulaire programmée (pd-1)
KR20250122541A (ko)	2022-10-25	2025-08-13	사이즈믹 테라퓨틱, 인코포레이티드.	변이체 IgG FC 폴리펩티드 및 그 용도
CN116284447A (zh) *	2023-02-20	2023-06-23	苏州大学	一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用
TW202500583A (zh) *	2023-03-17	2025-01-01	美商美國禮來大藥廠	Pd-1促效劑抗體及以pd-1促效劑抗體治療發炎或自體免疫皮膚疾病之方法
WO2025042732A1 (fr) *	2023-08-18	2025-02-27	Eli Lilly And Company	Anticorps agonistes de pd-1 et méthodes de traitement de maladies auto-immunes avec un anticorps agoniste de pd-1
CN120424213A (zh) *	2024-02-02	2025-08-05	英诺湖医药(杭州)有限公司	特异性结合pd-1的单克隆抗体及其医药用途
WO2026008665A1 (fr)	2024-07-01	2026-01-08	Vib Vzw	Liants du complexe pd-1•pd-l1 et leur utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101899114A (zh)	2002-12-23	2010-12-01	惠氏公司	抗pd-1抗体及其用途
DK2439273T3 (da)	2005-05-09	2019-06-03	Ono Pharmaceutical Co	Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
WO2009026472A1 (fr)	2007-08-21	2009-02-26	The General Hospital Corporation	Procédés pour induire une tolérance
AU2009290544B2 (en)	2008-09-12	2015-07-16	Oxford University Innovation Limited	PD-1 specific antibodies and uses thereof
US9181342B2 (en) *	2008-09-12	2015-11-10	Isis Innovation Limited	PD-1 specific antibodies and uses thereof
JP5844159B2 (ja)	2009-02-09	2016-01-13	ユニヴェルシテデクス−マルセイユＵｎｉｖｅｒｓｉｔｅＤ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ	Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US20130202623A1 (en)	2010-02-16	2013-08-08	Nicolas Chomont	Pd-1 modulation and uses thereof for modulating hiv replication
EP2545078A1 (fr)	2010-03-11	2013-01-16	UCB Pharma, S.A.	Anticorps pd-1
TW201134488A (en)	2010-03-11	2011-10-16	Ucb Pharma Sa	PD-1 antibodies
ES2893855T3 (es) *	2011-08-11	2022-02-10	Ono Pharmaceutical Co	Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
WO2014161509A1 (fr)	2013-04-05	2014-10-09	The University Of Hong Kong	Nouveaux isoformes de la pd1 et leurs utilisations pour potentialiser les réponses immunitaires
KR102357893B1 (ko) *	2014-08-05	2022-02-04	맵퀘스트 에스아	Pd-1 에 결합하는 면역학적 시약
US9982052B2 (en)	2014-08-05	2018-05-29	MabQuest, SA	Immunological reagents
KR20180019725A (ko)	2015-06-23	2018-02-26	메모리얼 슬로안-케터링 캔서 센터	신규의 피디 1 면역 조절제
BR112018006237A2 (pt) *	2015-09-29	2018-10-09	Celgene Corp	proteínas de ligação a pd-1 e métodos de uso das mesmas
ES2924402T3 (es)	2015-10-02	2022-10-06	Symphogen As	Anticuerpos anti-PD-1 y composiciones
ES2895034T3 (es)	2015-10-02	2022-02-17	Hoffmann La Roche	Anticuerpos anti-PD1 y procedimientos de uso
JP7003036B2 (ja)	2015-12-02	2022-02-04	エスティーキューブ，インコーポレイテッド	グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
CR20190550A (es)	2017-06-05	2020-04-05	Janssen Biotech Inc	Anticuerpos que se unen específicamente a pd-1 y métodos de uso

2019
- 2019-02-18 AR ARP190100406A patent/AR114127A1/es unknown
- 2019-02-18 TW TW108105310A patent/TWI708787B/zh active
- 2019-02-22 CN CN201980016779.7A patent/CN111886253B/zh active Active
- 2019-02-22 EA EA202091809A patent/EA202091809A1/ru unknown
- 2019-02-22 JP JP2020545727A patent/JP7071521B2/ja active Active
- 2019-02-22 CR CR20200375A patent/CR20200375A/es unknown
- 2019-02-22 AU AU2019228474A patent/AU2019228474B2/en active Active
- 2019-02-22 KR KR1020207024945A patent/KR102536014B1/ko active Active
- 2019-02-22 CA CA3092064A patent/CA3092064C/fr active Active
- 2019-02-22 WO PCT/US2019/019076 patent/WO2019168745A1/fr not_active Ceased
- 2019-02-22 MA MA052414A patent/MA52414A/fr unknown
- 2019-02-22 SG SG11202008437WA patent/SG11202008437WA/en unknown
- 2019-02-22 CN CN202411106937.7A patent/CN118846042A/zh active Pending
- 2019-02-22 EP EP19709336.2A patent/EP3759139A1/fr active Pending
- 2019-02-22 US US16/282,609 patent/US10493148B2/en active Active
- 2019-02-22 MX MX2020009124A patent/MX2020009124A/es unknown
- 2019-02-22 CN CN202411106932.4A patent/CN118903407A/zh active Pending
- 2019-02-22 BR BR112020015983-2A patent/BR112020015983A2/pt not_active Application Discontinuation
- 2019-02-22 CN CN202411106929.2A patent/CN118806891A/zh active Pending
- 2019-02-22 PE PE2020001188A patent/PE20210045A1/es unknown
- 2019-02-22 JO JOP/2020/0210A patent/JOP20200210A1/ar unknown
- 2019-02-22 KR KR1020237017035A patent/KR20230079458A/ko not_active Withdrawn
2020
- 2020-07-24 ZA ZA2020/04601A patent/ZA202004601B/en unknown
- 2020-07-28 IL IL276340A patent/IL276340A/en unknown
- 2020-08-05 DO DO2020000153A patent/DOP2020000153A/es unknown
- 2020-08-19 CO CONC2020/0010188A patent/CO2020010188A2/es unknown
- 2020-08-24 CL CL2020002180A patent/CL2020002180A1/es unknown
- 2020-09-01 EC ECSENADI202053544A patent/ECSP20053544A/es unknown
- 2020-09-01 PH PH12020551463A patent/PH12020551463A1/en unknown
- 2020-09-02 SA SA520420082A patent/SA520420082B1/ar unknown
2022
- 2022-03-07 JP JP2022034413A patent/JP7259107B2/ja active Active
2023
- 2023-04-05 JP JP2023061724A patent/JP2023093549A/ja active Pending
- 2023-07-10 AU AU2023204569A patent/AU2023204569A1/en active Pending

Also Published As

Publication number	Publication date
AU2019228474B2 (en)	2023-04-13
KR102536014B1 (ko)	2023-05-24
AU2023204569A1 (en)	2023-10-26
IL276340A (en)	2020-09-30
SA520420082B1 (ar)	2022-11-11
WO2019168745A1 (fr)	2019-09-06
CN111886253B (zh)	2024-08-27
CR20200375A (es)	2020-09-25
JP2022088411A (ja)	2022-06-14
JP7259107B2 (ja)	2023-04-17
SG11202008437WA (en)	2020-09-29
BR112020015983A2 (pt)	2020-12-15
KR20230079458A (ko)	2023-06-07
US20190270818A1 (en)	2019-09-05
CA3092064A1 (fr)	2019-09-06
CO2020010188A2 (es)	2020-08-31
CN111886253A (zh)	2020-11-03
DOP2020000153A (es)	2020-09-15
ECSP20053544A (es)	2020-10-30
PE20210045A1 (es)	2021-01-08
ZA202004601B (en)	2022-03-30
NZ766604A (en)	2024-10-25
CN118903407A (zh)	2024-11-08
CA3092064C (fr)	2024-01-02
CN118846042A (zh)	2024-10-29
TW201942133A (zh)	2019-11-01
JP2023093549A (ja)	2023-07-04
EA202091809A1 (ru)	2020-11-23
TWI708787B (zh)	2020-11-01
JP2021516235A (ja)	2021-07-01
AR114127A1 (es)	2020-07-22
MX2020009124A (es)	2020-09-28
JOP20200210A1 (ar)	2020-08-30
JP7071521B2 (ja)	2022-05-19
AU2019228474A1 (en)	2020-08-20
CL2020002180A1 (es)	2021-01-04
EP3759139A1 (fr)	2021-01-06
US10493148B2 (en)	2019-12-03
KR20200115614A (ko)	2020-10-07
PH12020551463A1 (en)	2021-09-01
CN118806891A (zh)	2024-10-22

Publication	Publication Date	Title
MA52414A (fr)	2021-01-06	Anticorps agonistes de pd-1 et leurs utilisations
EP3891183A4 (fr)	2022-08-31	Anticorps anti-claudine et leurs utilisations
EP3759143A4 (fr)	2022-03-02	Anticorps anti-tigit et leurs utilisations
MA52773A (fr)	2021-04-14	Anticorps anti-cd3 et leurs utilisations
EP3762030A4 (fr)	2022-01-05	Anticorps anti-cd73 et utilisations associées
EP3625263A4 (fr)	2021-05-05	Anticorps anti-galectine-9 et leurs utilisations
MA52949A (fr)	2021-04-28	Anticorps anti-pd-1 et leurs utilisations
MA49687A (fr)	2020-06-03	Anticorps anti-ctla-4 et leurs utilisations
EP3918323A4 (fr)	2022-12-28	Anticorps anti-gal3 et leurs utilisations
EP3383916A4 (fr)	2019-09-11	Anticorps anti-cd73 et leurs utilisations
MA47789A (fr)	2020-01-22	Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr)	2019-08-14	Anticorps anti-lag-3 et leurs utilisations
MA49886A (fr)	2020-06-24	Anticorps anti-par2 et leurs utilisations
EP3589660A4 (fr)	2021-04-07	Anticorps anti-pd-l1 et utilisations associées
EP3735427A4 (fr)	2021-09-15	Anticorps anti-mct1 et utilisations associées
EP3790586A4 (fr)	2022-01-19	Anticorps anti-dll3 et leurs utilisations
EP3645563A4 (fr)	2021-03-17	Anticorps anti-fam19a5 et leurs utilisations
EP3661555A4 (fr)	2021-07-14	Anticorps bispécifiques et leurs utilisations
EP3850012A4 (fr)	2022-06-15	Anticorps anti-tnfrsf9 et leurs utilisations
EP3755714A4 (fr)	2022-02-16	Anticorps anti-angiopoïétine-2 et leurs utilisations
EP3672987A4 (fr)	2021-08-18	Anticorps anti-apéline et leurs utilisations
MA54469A (fr)	2021-10-20	Anticorps anti-il-27 et leurs utilisations
EP3755716A4 (fr)	2021-08-04	Anticorps anti-pd-1 et leurs utilisations
MA49133A (fr)	2020-03-25	Anticorps agonistes anti-btla et leurs utilisations
MA52190A (fr)	2021-02-17	Anticorps anti-trem-1 et utilisations associées